Abstract-In a positron emission tomography (PET) study, the local uptake of the tracer is dependent on vascular delivery and retention. For dynamic studies the measured uptake time-course information can be best interpreted when knowledge of the time-course of tracer in the blood is available. This is certainly true for the most established tracers such as -Fluorodeoxyglucose (FDG) and -Water (H O). Since direct sampling of blood as part of PET studies is increasingly impractical, there is ongoing interest in image-extraction of blood time-course information. But analysis of PET-measured blood pool signals is complicated because they will typically involve a combination of arterial, venous and tissue information. Thus, a careful appreciation of these components is needed to interpret the available data. To facilitate this process, we propose a novel Markov chain model for representation of the circulation of a tracer atom in the body. The model represents both arterial and venous time-course patterns. Under reasonable conditions equilibration of tracer activity in arterial and venous blood is achieved by the end of the PET study-consistent with empirical measurement. Statistical inference for Markov model parameters is a challenge. A penalized nonlinear least squares process, incorporating a generalized cross-validation score, is proposed. Random effects analysis is used to adaptively specify the structure of the penalty function based on historical samples of directly measured blood data. A collection of arterially sampled data from PET studies with FDG and H O is used to illustrate the methodology. These data analyses are highly supportive of the overall modeling approach. An adaptation of the model to the problem of extraction of arterial blood signals from imaging data is also developed and promising preliminary results for cerebral and thoracic imaging studies with FDG and H O are obtained.
I. INTRODUCTION

I
N POSITRON emission tomography (PET), kinetic analysis of the dynamic time-course of the radiotracer uptake is used to help distinguish vascular delivery of the tracer from its metabolic retention. This facilitates a better understanding of the information contained in the PET imaging study and can lead to enhanced image-derived variables for consideration of disease diagnosis and prognosis. But most kinetic modeling in PET relies on having the time-course of the tracer in the arterial plasma as an input. Increasingly, in clinical and small animal studies with PET, direct measurement of the arterial plasma input is problematic and as a result there is substantial interest in using more limited data, even the imaging data itself, to recover this quantity. For some recent work in this direction, see [7] , [11] , [21] , [23] , [39] , [47] for example. It should be emphasized from the outset that although the arterial plasma concentration of the tracer is the input for kinetic models, the direct measurement of plasma concentration may not always feasible. But if the arterial whole blood activity is known (or estimated) it may be used to infer the plasma concentration [17] . Throughout this work we use the abbreviation AIF (arterial input function) to refer to the arterial whole blood. Since the AIF is a function, its evaluation from limited data is not straightforward. The intrinsic high/infinite dimensionality of the AIF is an issue. With high-dimensionality there is always an estimation theory trade-off between bias and variability [24] , [43] . A very flexible parameterization may lead to statistically unreliable AIF estimation. Hence, a parsimonious physiologic representation of the AIF has some benefit. In previous work we considered an adaptable template model for AIF representation [37] , [39] . While this approach was shown to be effective, there are contexts when the available data may be venous blood samples, these are easier to acquire, or where the measurements may arise from a mixture of information from venous and arterial blood, because venous and arterial vessels are often adjacent. To address these situations a comprehensive representation of tracer activity in circulating blood and its components is desirable. Here, we propose a stochastic model and develop a statistical methodology for its practical implementation.
A variety of approaches are available for modeling the whole body clearance kinetics of circulating drugs. The most widely used methods, which fall into the category of physiologically based pharmokinetic (PBPK) models, are based on compartmental modeling constructs [2] , [19] . These models describe the transfer and transformation of a drug by continuous-time changes in concentrations of the original molecule and its metabolites in physiologically defined compartments or spaces within the body. Adaptations of the PBPK approach that allow for heterogeneity are also available (Norwich [35] has an excellent review). Compartmental models are usually formulated as systems of differential equations for continuous variables describing the concentration of drug. However, the fate of individual drug molecules is determined by a discrete process involving individual interactions with transporters and enzymes, etc. Hence it is perhaps more natural to view evolution of the drug concentration described by the compartmental model as a limit of averages of Markov jump process variables describing the continuous-time trajectory of individual drug molecules. This point of view is well developed in the stochastic process literature (see [1] , [22] , and [34] ). Direct consideration of the Markov approach also allows one to consider alternative time-steps. We consider a model in which time-steps are linked to beats of the heart. The resulting Markov chain model is implemented with full reliance on spectral decomposition of the transition probability matrix for the chain. Efficient numerical evaluation of time-course patterns is reduced to rapid exponential-like convolution formulas of the type one would have with standard compartmental models. This is seen to provide a convenient and efficient evaluation of model output signals.
The inference for model parameters is complicated by the nonlinear relation between model output signals and individual parameters defining the Markov transition matrix. The requirement for the model to be physiologically realistic, not just a predictive device for comparison with measurable outputs, forces attention on estimation methods that perform well with high-dimensional parameters. Bayesian and more approximate penalty or regularization methods are naturally suited to such problems [39] , [43] . Indeed, such approaches are already used in the PBPK literature (cf. Yang et al. [46] ). Here, we adapt a random effects modeling structure to construct a penalty function from historical data. This approach is tested using data from PET studies with -Fluorodeoxyglucose (FDG) and -Water (H O)-the two most established PET tracers in medical research. The results obtained are satisfactory. The last part of the work presented here provides a procedure for application of the Markov model to the problem of extracting blood signals from PET-measured region of interest data. Such regions might be defined interactively or, as we do here, produced by an image segmentation process [38] . The proposed procedure entails representation of the uptake data as a linear combination of blood signal components and a component (driven by arterial blood) representing the interaction of the tracer with the tissue. Estimation recovers the Markov model parameters from which the output blood signals, and in particular the AIF, are produced. We demonstrate this approach with cerebral and cardiac region data from dynamic PET studies with FDG and H O.
The outline of the paper is as follows. Section II describes the basic model and its numerical implementation. Inference procedures for sampled data and for definition of the penalty function are developed in Section III. Section IV applies these tools to measured arterial data. The application to image-based extraction is developed in Section V, together with illustrations. The paper concludes with some discussion.
II. MODEL AND ITS ANALYSIS
Our model describes the fate of individual tracer atoms with the limiting probability distribution of the collection of these atoms then being used to describe decay-corrected tracer activity concentration. To track the tracer atom circulation, the body is divided into distinct physiologic compartments which the tracer atom has a nonnegligible probability of accessing during the course of the PET study. There are a range of possibilities here but for our purposes a set of eight compartments are studied: the right ventricle and left ventricle of the heart, vascular and extra-vascular tissue involved in the lung and vascular and extra-vascular tissue in the body. In addition there is the venous blood and a sink , such as the bladder, from which tracer absolutely cannot return to circulation (see Fig. 1 ). Note our model considers tracer atoms, irrespective of whether the isotopes on those atoms have decayed or not-thus the model predicts decay-corrected counts.
Since circulation of blood in the body is driven by the heart, it is natural to link movements of the tracer to beats of the heart. We use a Markov chain approach [34] is a good general reference here. The model considers the fate of a tracer atom, initially introduced to the right ventricle through a convenient radial vein on the zeroth heart-beat-assumed to be the time of injection. Let be the location of the atom on the th beat;
takes values in the 8-D state-space (see Fig. 1 ). Considering the various individual interactions experienced by a tracer atom in the body, the change of location of the atom from one beat to the next is best viewed as a random process. Furthermore, it is reasonable to assume that the state occupied on the next beat only depends on the current state. In other words we regard as a Markov process. Of course we assume that the physiology does not change appreciably over the time-frame of the PET study, so is a Markov chain whose stochastic properties are governed by a time-invariant transition matrix with (1) for . Fig. 1 presents a graph of the one-step transitions and associated probabilities. This is a finite state Markov chain. Let denote the probability distribution of the state of the atom on the th beat-i.e., for . From standard theory, if there is no loss , the ejection probabilities are strictly positive and the compartment resting probabilities are all strictly less than unity, then all states (apart from the sink ) communicate. As the vascular state in the lung or the body is clearly aperiodic, all states are aperiodic. It follows that provided converges to a distribution over the other states, i.e., as (see [34] ). Writing the defining equation for the stationary distribution over the nonsink states, , is readily solved to obtain (2) 
Since , this analysis shows that the tracer atom frequency in the venous and arterial pools equilibrates over time, provided there is no loss. One should realize that the physiological state over the course of the tracer measurement (4-6 min for a typical H O study or 60-90 min for an FDG study) will not apply over much longer periods of time. Thus, the configuration achieved by the end of the PET study will generally deviate from the physiological distribution of the substrate in the body. So while most water in the body sits in extravasculature, this does not provide a guide for the probability that a tracer atom will be in the extravasculature by the end of a dynamic PET study with H O. A further point to bear in mind is that the Markov model describes the total number of tracer atoms, i.e., the amount of tracer, not its local concentration. It is necessary to normalize amounts by the local volume of a particular whole body state in order to obtain a local activity. Fig. 2 presents output profiles of the model with parameter configurations optimized to fit a measured decay-corrected arterial whole blood time-course for H O and FDG. The details of the fitting process are described in Section III. The fitted arterial profile is scaled to match the measured arterial data, the corresponding venous profile is then scaled to match the arterial profile at late times. The analysis above shows equilibration of the distribution of tracer atoms in arterial and venous pools in the model and since the arterial and venous blood volumes are the same, the predicted arterial and venous whole blood concentrations will match at late times. The profiles shown for RV and lung are illustrative. Further information, e.g., blood volumes, would be needed to give absolute scaling. For image-based AIF extraction we will see that the analysis relies on the model only providing profile shapes (see Section V). It is also worth highlighting here that the model has the potential to represent the peak area of the arterial blood signal in a more resolved manner than might be possible based on sampling alone, this is seen in Section V.
A. Evolution of an Injected Profile and Its Computation
If a (possibly random) number of tracer atoms are introduced on the th heart beat, the distribution of these atoms on the th beat is given by an 8-D vector . follows a multinomial distribution with trials and success probability where is the impulse for is the impulse response. If a sequence of inputs are introduced to state 1, the total number of atoms is a sum of independent multinomials
The expectation of is given by the discrete convolution with the impulse response Of course, tracers are introduced in a continuous manner and measured at arbitrary time points as well. Let for be the activity of injected tracer per ml of blood as a function of time and let be the resultant activity of tracer in the various model states as a function of time. Individual heart beats occur at (possibly random) times . Letting be the number of heart beats up to time If where is the volume of blood circulated on the th beat, then conditional on , the expected activity of tracer in each state as a function of time is Consequently, if the expected number of beats per unit time is , and is constant then by replacing the values and by their expected values and , we predict the tracer activity in each model state to be (4) where and is the integer part of . We should emphasize that although the Markov model was specified for individual tracer atoms, it produces predictions for decay-corrected tracer activities.
Computation: Efficient numerical evaluation of is achieved by means of the spectral decomposition of the transition matrix . We write where is a diagonal matrix containing the eigenvalues of , and the rows of are the corresponding eigenvectors (both possibly complex). Classical Perron-Frobenius matrix theory tells us that the eigenvalues of the transition matrix can be ordered by decreasing size of modulus (5) if there is no loss and . Letting the rows of be given by and the columns of by then (6) so where for . Note that when there is no loss, converges to the unique stationary distribution and . Thus, (7) where is the convolution between the sequence and the (possibly complex) sequence . The recursion and for allows rapid evaluation of the convolution. This can be further refined if admits a piecewise constant approximation. This is often the case because typical input functions arise from infusion of tracer over a short period of time and as a result will be close to zero for a long period of time.
III. MODEL INFERENCE
Similar to compartment models used for kinetic analysis of PET time-course data, the time-course of tracer in the blood (sampling any of the identified spaces in the model or even a combination thereof) should allow the estimation of unknown parameters in the Markov model. We illustrate this for the case where data are obtained by direct sampling of the radial artery. Our model describes the arterial signal in the left ventricle which, up to timing, should match the radial artery time-course. Collections of arterially sampled data are available for many tracers, particularly for PET studies with H O and FDG. We consider these below. Because of the large number of parameters in the model, relative to the typical number of arterial measurements, it is necessary to employ a regularization/penalty approach for estimation (cf. [39] for a similar context in which this is used). A simple variation on a ridge regression strategy is employed with a generalized cross-validation procedure for adaptation of the regularization parameter. A Bayesian analysis is proposed for adaptation of the form of the penalty function.
Let the time-course data be given by for , where the scalar represents the arterial tracer concentration measured at time and is a measure of the reliability of this measurement. The weights might be supplied with the measurement but without any information we take them to be uniform. The data are modeled as (8) where are . with mean zero and unknown variance is obtained by scaling the arterial time-course produced by the model. The parameter vector specifies the transition matrix , the input function structure and a scale parameter. For the data we consider here, the injected profile can be assumed to be a square wave arising from the introduction of a specified volume of tracer solution infused into the venous site over a known time-period . But since dispersion of this idealized signal can arise within the venous vessel, en route to the heart, a convolution with a two-parameter gamma density is needed to accurately represent the signal arising at the right ventricle of the heart (see [29] for more elaborate consideration of the dispersion problem). In addition there is a timing consideration-the measured data may not be coincident with the timing of the injection, so there is a need for a parameter , positive or negative, to account for this. Thus, the input injection is where is an indicator function for the interval and is the cumulative distribution function of a Gamma variable with unit scale and shape . Based on these considerations (9) where is the time course in the arterial component of in the model using the input function above. is a scaling factor which theoretically is inversely proportional to the volume of arterial blood. Depending on the units of it maybe necessary to adjust for calibration factors. is assumed to be an unknown parameter.
A. Parameterization
There are a total of 14 unknowns in the model-. A priori considerations allow specification of the heart rate and the injection duration . Thus, the number of free parameters is 12. Apart from , the parameters must be nonnegative but there are further more complex constraints arising from the requirement that the transitions must be probabilities with a unitary row sum. The transformations (10) provide a convenient set of variables for parameterization of the transition matrix. Initial experience in fitting the model to real data found that and could be taken to be less than unity without affecting the fit. In light of this, we subsequently imposed this as a constraint. Using a combination of logarithmic and logistic transforms, the elements of (11) are mapped to the unknown parameters according to and with the transition matrix parameters are given by (12) where and .
B. Regularization With a Penalty Function
As information in the data is quite limited (note the number of data points might typically be on the order of 30-50) relative to the number of parameters to estimate, a penalized weighted nonlinear least squares (NLS) criterion is used for estimation, see [36] , [43] for some background on this methodology. The objective function is (13) for . The choice of and the nonnegative definite matrix are adapted to the specifics of the tracer (see below). As gets large the estimator is reduced to the value , this is appropriate in very high noise situations. With low noise, should be made small so that the standard NLS estimator is obtained. A data-adaptive choice for based on cross validation is described below. For computation, the NLS code of Dennis and Schnabel [9] as implemented in R [41] is employed. This entails spectral analysis of the quadratic form so that the objective function is expressed in terms of standard weighted nonlinear least squares. The residual sample variance is The R NLS code provides as output an approximate unscaled covariance matrix where is the matrix with rows and is the diagonal matrix with elements .
, even if scaled by , can be manipulated to provide an estimate of variance and also an estimate of the effective degrees of freedom for . This is something which is needed for computation of our generalized cross-validation score. Note (up to the usual first order linearization of ) the sample covariance matrix of is (14) Here, might be referred to as the bias-operator [5] . The eigenvalues of must lie between 0 and 1. Also as and as . If and do not enter the penalty,
. Thus, the model degrees of freedom is approximated as (15) Following [36] , the generalized cross validation (GCV) score is (16) with the minimizer of this function used to define the estimate of . This estimate is denoted .
C. Use of Population Data for Penalty Specification
Here, we show how population data can be used to specify the parameters, specifically and , in the penalty function. Given a collection of data for the tracer on different subjects, a population distribution for model parameters can be constructed. This could then be used in a Bayesian fashion to appropriately adapt the penalty parameters for a particular tracer. We elaborate on the approach. Suppose blood time-course data from subjects are available A plausible random effects model for the data is (17) where are . with mean zero and unit variance and the vectors are also . with mean zero and common covariance . Procedures for computation of maximum likelihood estimates of and have been well developed in the literature. While direct consideration of the marginal likelihood of the measured data could be considered, we opt for the EM method which allows a more immediate implementation in R. The development here follows Mentre and Gomeni [28] and Walker [44] . In large samples, the weighted least squares estimate of (call this ) can be approximated in terms of a linear model (see [45] ) (18) where is a vector of . Gaussian random variables with mean zero unit variance. Here, is the sensitivity matrix (with rows for ) and is a diagonal matrix formed from the with weights . Thus, with the approximation in (17), the distribution of given and is Gaussian with mean and covariance given by where . Here, it is important to recognize the dependence of and on the unknown population mean and covariance . Via EM analysis, this leads to score equations for and as (19) where . The above equations are nonlinear in and ; this is because both and are functions of and . The EM algorithm amounts to using current iterates for and to evaluate and -these are computed as the minimizer and inverse Hessian for the penalized nonlinear least squares problem in (12) with penalty function -and then evaluating the right-hand sides of (19) to update. Thus, in our implementation there is iterative use of the NLS codes in R. At no stage does calculation involve evaluation of the expressions in (18) as these would entail computation of the more unstable weighted least squares estimates in (17) . This is an attraction of the EM approach.
IV. APPLICATION TO DIRECTLY SAMPLED ARTERIAL DATA
We now present some sample illustrations of the model and its performance. The data are from PET imaging studies with FDG and H O. FDG is the most commonly used tracer in clinical PET imaging, particularly in cancer applications. The 109.77 min half-life of the isotope allows the possibility for FDG to be prepared off-site and subsequently transported to the PET scanning unit. H O is the gold standard for in vivo quantitation of blood flow and perfusion. The short 2.033 min half-life of the isotope limits its widespread use in clinical settings but there are a range of physiological studies that can only be measured using this approach. There are more approximate but simpler approaches to perfusion and flow assessment, using dynamic contrast enhanced MR and dynamic contrast Computerized Tomography, but in cases where absolute quantitation is needed researchers turn to H O.
We consider data acquired over several years as part of ongoing clinically focused PET research projects based at the University of Washington. It is a mixture of normal subjects, as well as patients with cancer conditions [8] , [14] , [30] , [39] , [42] . All studies considered had direct arterial sampling of the PET tracer. This involved insertion of a radial artery catheter and the sampling and analysis of arterial blood via an online sampler [13] , [16] . Tracer injection was by a bolus (delivered over 5-10 s) in H O studies and by automated infusion over 1 or 2 min with FDG. Following injection, H O studies had durations of between 3 and 6 min while FDG were typically 90 min in duration. Tables I and  II) and template fit (left).
Direct measurement of the injection line activity profile was not available, thus we do not have direct validation on whether the input exactly matched the target-in practice variations can and do happen. For each tracer postinjection sampling was initially rapid (typically 2 s for H O; 10 s for FDG) and allowed to be progressively less frequent afterwards (up to 15 s frequency for H O and 5-10 min frequency for FDG). A set of 97 H O and 91 FDG arterial curves are considered in this analysis. Before presenting analysis of real data, we first present some simulation results.
A. Simulation Study
We simulated blood time-course data (with parameters matched to values found on real data). For each simulated dataset, the nonlinear least squares procedure was applied to estimate model parameters. Studies with blood sampling protocols matched to our FDG and H O series were employed. The measurement error used in simulations was Gaussian with percent variance estimated on the basis of real data-higher/lower noise cases being obtained by multiplication/division of the real noise variance by a factor of four. As we had some concern that the smoother venous blood signal might significantly impact the estimation characteristics, studies with simulated arterial and venous data were carried out. Estimation performance is evaluated as the average absolute percentage error between the estimated and true parameter values-i.e., where specifies the number of dimensions of . Simulation results are shown in Fig. 3 .
The estimation process is seen to correctly respond to noise, demonstrating consistency. In addition it is clear that either arterial or venous information can be used to recover parameters. The error rates are similar. This is important as blood signals available via imaging typically include contributions from arterial and venous blood. We also note that the error rates for FDG and H O are not significantly different. Fig. 4 shows results of the application of the model to sampled arterial FDG and H O data illustrating the role of the penalty function. The fit of the model is seen to closely match the observed data. The data are also analyzed using a further model based on an adaptable template developed in et al. [39] . It provides a very reasonable representation of the arterial data as well. But of course it does not provide predictions for separate blood pools that can be described by the Markov approach. The methodology was applied to the collection of arterially sampled FDG and H O curves. For each curve three fits were obtainedthe template model [39] , the Markov model with the population-adapted covariance and also the fit of this model using a diagonal covariance. A boxplot summary of the scaled residual sum of squares for the fits to all available sampled arterial data was constructed. For scaling we used the tail region data (2 min beyond the peak in H O and 40 min after the peak for FDG) to derive an estimate of the measurement error standard deviation which was then used to scale the overall residual sum of squares fit. This procedure enabled us to compare the fits of curves based (12) on different injected doses and also ones in which the sampling was more frequent with smaller volumes of blood sampled to cases where the sampling is less frequent but larger volumes of blood per sample are involved [13] , [16] . Over the collection of curves considered, the Markov model achieves clear statistical improvements over the template approach. There is a much less dramatic improvement obtained using the "optimized" correlation structure in the penalty. Thus, the penalty approach demonstrates some robustness to the precise specification of the covariance. This is not inconsistent with the general behavior of penalty, shrinkage and regularization estimators in other theoretically similar contexts (see [5] , [6] , [24] , [43] ). Tables I and II present the population extracted mean and covariance matrix (diagonal variance and correlation) of the parameters in the model.
B. Analysis of Real Data
V. IMAGE-BASED EXTRACTION OF AN AIF
We now explore how the Markov chain model might be applied to extract blood profiles from dynamic PET imaging data. Consider first the case where there is a single region of interest (ROI) in the field of view of the PET scanner with a significant blood pool signal. Such a region might be defined interactively or guided by use of a segmentation procedure designed to identify regions with characteristic time-course patterns of the type associated with a blood signal [39] . We present examples below. The basic equation of PET imaging, says that the time-course at a point is (under assumptions of linearity and time-invariance of the tissue response to the tracer) considered as a convolution between the arterial input signal and the tissue residue (or impulse response), see e.g., [15] , [18] , [27] , [40] . Instrumental and physiological factors (including organ motion), limit resolution so that voxel-level data is best viewed as a mixture of signals arising from inputs in the vicinity of the voxel [12] , [38] , [40] . Remote from the heart and the injection site only arterial and venous blood pool signals would be present. Here, if we consider the time-course produced by averaging over individual voxels in the ROI and assume we can ignore dispersion effects (perhaps because the region is not sufficiently large), the regionally averaged PET measured activity at time can be modeled as a linear combination of venous, arterial and tissue contributions as follows: (20) where and is the regional tissue residue (impulse response) and represents a combination of measurement and modeling error. The scale factors convert total (decay-corrected) activities predicted by the model to the activity per ml (or cc) units of the PET measurements. Thus, the -values are inversely proportional to blood volumes. Since the resolution of the scanner plays a role, the -values will be affected by that. Expressing the venous and arterial signals in terms of our whole body circulation model we obtain (21) with and .
We could also allow for delay/advance between the appearance of these signals at the heart and at the tissue region. This has not been found critical. Here, one could argue that were the venous and arterial signals to arise close to the heart, the arterial signal at a tissue would be delayed while the venous signal would be in advance of that at the heart. However, our whole body model is not configured to carefully localize the arterial and venous signals in this manner so we use a common alignment procedure for representation at the tissue. This aspect could be refined by inclusion of a more elaborate representation of the venous and arterial spaces in the model (e.g., by use of BTEX type models [3] ). In regions close to the heart, additional blood signals are relevant. In particular we would expect contributions from the right ventricle, lung and perhaps even the input prior to entry to the right ventricle. We can augment the above model to include these noting that they are localized to the heart. Thus, if is extended to include weights for the right ventricle and vascular lung components, and
The precise timing of PET scans relative to the start of the injection can sometimes be uncertain and hence there is a need to allow for a delay parameter which aligns the model with the PET data. This gives An objective function for assessment of can be derived from this. The weighted residual sums of squares misfit between the observed data and the model is (22) Here, are inversely proportional to the variance of the -measurements (see [15] for example). For fixed , we can optimize the objective function with respect to and , so as to derive a profile objective function for determination of (23) where and and are the optimized values for and given . We have not specified the form of but, noting that its structure coincides with that of a survival curve observed over finite duration, relevant monotonicity and positivity constraints allow its estimation (jointly with the parameters) to be readily achieved by standard quadratic programming methods [15] , [40] . A practical procedure for doing this has been developed in the open-source R statistical package [15] , [41] .
The objective function for assessment of can be augmented to include information from a collection of, say , ROIs constructed from the same study. Adding in a penalty term, whose construction is developed in Section IV, gives the overall criterion (24) where and are activity values and weights for the 'th ROI and is the optimized, conditional on , to fit for the data from that ROI. As before, is a regularization parameter. This follows the general structure of the approach described in [39] .
Numerical optimization of using gradient-based procedures [9] , is nontrivial. This is particularly so in the environment offered by R [41] . We adopt a sampled approach to approximated optimization that is easily implemented in R. While alternatives to R could certainly be employed, the fact that we have an approach that produces acceptable results using an opensource package is positive. A simplified procedure is to consider a set of possible configurations for the model and use the objective function to select among those. Our present implementation adopts that approach. With H O and FDG, the analysis of our historical collection of arterial data (in Section IV above) yields a plausible set of model configurationsfor H O and for FDG. So these configurations can be evaluated by the to select the optimal model for a given H O or FDG study. If we consider the collection of historically derived configurations as a discrete prior distribution (with equal mass on each configuration), a formal Bayesian interpretation can be attached to this scheme. We are selecting the model at the mode of the posterior distribution; the posterior mean configuration could also be considered. Arising from this interpretation, one might expect the approach to inherit advantages that typically follow many empirical Bayesian methods [24] . Established theory, e.g., [43] , gives that the regularization function for is a Lagrangian form for a method of sieves estimator: minimize subject to , where . In the discrete setting of our approximate optimization procedure, there are only a finite set of possible values for . With FDG these are (25) for . Hence minimum (in the available configuration of values) of subject to is easily found. These -values describe the full set of possible regularization estimators possible. To choose among these we need to select a value for . Our approach is to be guided by the a priori empirical distribution of -specifically the th percentile of that distribution. Our experience is that any choice of in the range [0.80, 1] is adequate here. Note the value of entails no regularization. A data-dependent choice of by cross-validation could be considered, however, in view of the rather satisfactory results we have obtained, there is not a critical need for that now.
A. Scaling Without Supplementary Blood Measurements
If sampled arterial or venous data were available, it would be possible to use that to scale the reconstructed input functions. Studies in which there is a large blood-pool in the field of view, e.g., the heart, allow the possibility to directly scale based on a recovered late time image value. In a cerebral imaging setting, Fung and Carson [11] report that the availability of supplementary anatomic (MR) information and careful analysis of PET point-spread may provide an opportunity to scale AIFs recovered for PET-H O studies. We focus on the case where there is no blood measurement available for scaling. Our model predicts the total activity of tracer in circulating arterial blood. If most of the tracer remained in the circulating blood over the course of the study, the late time arterial blood activity should match the injected dose per unit volume of blood. Nalder et al. [32] established an empirical formula that allows prediction of an individual's blood volume in terms of their gender, weight and height, we refer to this as the NBV (Nalder blood volume). This may allow the recovery of arterial activity per unit blood volume. We adapt this approach based on our historical data. As reported in Section IV we fit the blood model to these data. Let be the predicted arterial activity at time in response to a bolus input. The ratio of to the injected dose per NBV for that subject can be constructed-call this ratio . If the blood volume is accurate and is not too large, we would expect this ratio to be approximately unity. Given a collection of, say , arterially sampled blood curves, as we have available for FDG and H20, we can recover a collection of ratio values-for . The observed deviation of the ratio from unity is a function of physiologic factors describing blood circulation. As the blood model output encodes physiologic information, it seems reasonable to explore the predictability of the ratio value in terms of variables constructed from the blood model output. This can be done using established multiple regression techniques [45] . Our analysis finds an approximate linear relation between the -ratios and the late-time blood model bolus response vector-. Thus, the unknown scale-factor in (9) is given by the formula (26) with min for FDG and min for H O. The estimated coefficients and resulting error in the estimation of the scale factor is reported in Table III . The formula yields a cross-validated error rate of around 15% for FDG and 19% for H O. In the absence of arterial or venous samples we propose that this approach be used to scale blood curves. Once the arterial/venous profile is scaled, the venous/arterial profile is scaled on the basis that the late-time venous and arterial pools are in close equilibrium. We apply this approach below. 
B. Some Examples
To demonstrate the feasibility of the method we present a set of four illustrations using FDG and H O imaging studies conducted on a 35-plane GE-Advance scanner. There are two cerebral studies in the series, one with H O in a normal subject and the other with FDG in a brain tumour patient. The other two studies are from clinical H O and FDG studies in a breast cancer patient. These studies have been reported previously [10] , [14] , [30] . Blood curve reconstruction analysis is based on a collection of ROIs obtained from a complete segmentation of the 3-D data volume (excluding the arms in the breast cancer studies). This exclusion was achieved using the AMIDE [25] open-source image viewer. The segmentation procedure used is a split-and-merge algorithm designed to identify regions with characteristically shaped time-course patterns-this procedure is has been reported [38] , [39] . Nine regions were used with the cerebral studies and fifteen for the breast cancer examples. All examples use a regularization penalty with and the [see (25) ]. Figs. 5 and 6 present reconstructions of the arterial and venous (whole) blood profiles. For the cerebral studies we include the sampled arterial data; in the case of the breast cancer study, an image extracted LV signal is shown. In the cerebral studies the reconstructions show good correspondence with the measured data. For the H O case the arterial reconstructions is sharper than the radial artery data; for FDG there is closer peak agreement. With the breast data, the reconstructions are both somewhat sharper than the direct LV based measurement. In this case there is no adjustment for spillover in the LV derived profile so it image reconstruction might be expected to have a sharper peak. Overall the reconstructions appear quite satisfactory. Together with reconstructions we present maps of the local blood volume. This is computed using the parametric imaging technique described in Muzi et al. [31] . These maps though of poor resolution-these tracers are not primarily used to recover blood patterns-are remarkably well aligned with the expected blood distribution in the field of view. A number of representative analyses for the segment time-course data used in the reconstructions are also displayed. The spatial intensity of the segment time-courses are indicated. These illustrate how information from a range of different types of regions, highly vascular as well as ones with low vascularity, contribute to the overall reconstruction. To better appreciate this, we decompose the fitted tissue residue to distinguish the short-duration (rapid vascular flows) and longer-duration (extra-vascular) components of the model. Let be the break-point used to distinguish vascular from extra-vascular; minute is used in our displays. The vascular residue is and extra-vascular component is , where and denote the minimum and maximum of and . Thus, and we can write the residue based model prediction as a sum of contributions from short and long duration residue components. Substitution into this gives (27) where and .
C. Performance Data
The full series of 12 FDG and 22 H O PET scans in normal subjects from Graham et al. [14] and Muzi et al. [30] were considered. These data included measured blood input functions recovered from from catheterized sampling of a radial artery. Time-course data for a number of brain structures were also available. These were recovered manually with careful reliance on co-registered high-resolution MR scans. For FDG there were 10 regions of interest (ROIs) in each of 12 studies to giving a total of 120 ROI datasets. The regions were: cerebellum, temporal, frontal, parietal, and occipital cortex, thalamus, putamen, caudate, whole brain and white matter. For H O, in each study had between six and nine ROIs leading to a collection 184 ROI datasets. The regions in these studies included: choroid, pituitary and salivary gland, ventricle, selected whole brain regions, white and gray matter. In Graham et al. [14] and Muzi et al. [30] , these ROI data were analyzed using the conventional compartmental models using the sampled arterial time-course as an in-out function. The one-compartment Kety-Schmidt model is used for H O and two-compartmental Sokolov-Huang model is used for FDG. With H O the 1-Compartment model has two kinetic constants and a fractional blood volume term; with FDG the 2-Compartment model has four kinetic constants and a fractions blood volume term. Model formulas and standard details of the model are given in Huang and Phelphs [18] for example.
For each scan we applied the analysis procedure to recover an image-extracted arterial blood curve. ROI data were analyzed using the compartmental models, using both the sampled-arterial data and the image extracted arterial reconstruction as an input. We compared the kinetic constants recovered for all ROIs using the sampled arterial input function to the kinetic values obtained when the data are analyzed using the image extracted input function. With H O we focus on flow and blood volume; for FDG the focus is on flux Fig. 7 . Performance of AIF extraction. Comparison between kinetic parameters for ROI data sets analyzed using relevant compartmental models, the Kety-Schmidt model for H O and the Sokolov-Huang model for FDG [18] , and either the image-extracted or the arterially sampled blood input function. The line of identity is shown in grey, the least-squares line is in black. The top row is for H O; the bottom is for FDG.
and volume of distribution . Fig. 7 compares the values of these parameters recovered using the image-extracted and sampled arterial input functions. Overall the results are quite satisfactory. The agreement for Flux on FDG is the strongest. The results for H O flow and blood volume, though still reasonably well aligned, show more variation. This probably reflects the propagation of variability in the data through the nonlinear estimation process, more than scale uncertainty. With FDG we see a systematic tendency to produce higher volume of distribution values using the image extracted technique-20%-30% higher. This is related to a general tendency for the image extraction procedure to recover slightly sharper input functions. Some of this of course might reflect a real difference between the level of dispersion in the radially sampled vessels relative to the undoubtly lower level of dispersion in the larger vessels that supply blood to the brain.
VI. DISCUSSION
We have developed a new model for representation of tracer concentrations in circulating blood. The approach is based on a Markov chain representation with time-steps directly connected to beats of the heart. Statistical analysis finds good agreement between the model and measured arterially sampled data. The possibility to integrate an understanding of past curves into the analysis of future data is also illustrated.
The model has been adapted for use in the context of blood curve extraction with PET data and some illustrative examples are presented. A novel scaling procedure is also described. A study with a series of cerebral scans with FDG and H O yields is included. Overall the approach shows promise and may help to refine techniques used for image-based extraction of blood information from PET studies in which there is limited opportunity for direct arterial sampling. Further validation of these techniques with a more extensive series of PET imaging studies is merited.
